Coherus Biosciences Reports Winning of Pegfilgrastim Patent Dispute Against Amgen

Coherus Biosciences’ Udenyca (Pegfilgrastim Biosimilar) Receives EU Marketing Approval for Febrile Neutropenia


  • Coherus announces the Federal Circuit affirmation decision of the US District Court for the District of Delaware appealing that Coherus’ Udenyca (biosimilar, pegfilgrastim) does not infringe Amgen’s asserted patent 
  • On May 10, 2017 under BPCIA act, Amgen filled a patent infringement complaint against Coherus asserting US Patent 8,273,707 (“the ’707 patent”), further in response Coherus filled lawsuit for dismissing the dispute. In Mar’18 the Delaware Court dismissed the whole case
  • Udenyca (pegfilgrastim-cbqv) is a s a PEGylated growth colony-stimulating factor targeted to decrease the incidence of infection, manifested by febrile neutropenia, in patients with non-myeloid malignancies myelosuppressive anti-cancer drugs

Click here to read full press release/ article | Ref: Coherus Biosciences| Image: SmarterAnalyst